MEDICINE
hamburger

CML is a myeloproliferative disease that develops at the time the Philadelphia chromosome appears. It presents an abnormal proliferation of immature granulocytic cells that are displacing the normal cellular population. Its treatment is based on administration of oral tyrosine kinase inhibitors. Adherence is critical to achieving disease control.


It is indicated for the treatment of adults with: chronic myeloid leukemia (lmc) with Philadelphia chromosome positive (ph +) in chronic phase of recent diagnosis. Lmc ph + in chronic, accelerated, or myeloblastic or lymphoblastic phase with resistance or intolerance to previous treatment, including imatinib. Acute lymphoblastic leukemia with Philadelfia chromosome positive (lla ph +) with resistance or intolerance to previous treatment.

  1. NCCN Guidelines Version 2.2017 Updates Chronic Myeloid Leukemia
  2. Alikian M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif 2017; 11: 4-20.
  3. Wei et al.: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology & Oncology 2010 3:47.
  4. Agrawal M, Garg RJ, Cortes J, Quintas-Cardama A: Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010, 5:70-80.
  5. Huang R, Kang Q, Liu H, Li Y. New insights into the molecular resistance mechanisms of chronic myeloid leukemia. Curr Cancer Drug Targets 2016; 16: 323-45.
  6. Tortorella SM, Hung A, Karagiannis TC. The implications of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia. Antioxid Redux Signal 2015; 22: 1425-62.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?